Tomahawk, WI 05/22/2014 (Basicsmedia) – ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), a clinical-stage company based in Los Angeles, announced their detailed financial estimate of the first quarter on March 31, 2014. The company survived a loss of $3.2 million, valued at a loss of $0.05 per diluted share. However, in comparison to the garbled loss of $5.0 million (or $0.10 per diluted share) in Q1-2013, losses in the last quarter, showed the company staggering at a better front, comparatively.

Cash utilized in Q1-2014 on myriad operational tasks stood at $2.6 million, whereas, cash expended in Q1-2013 amounted to $2.2 million. Increase in cash usage in the last quarter was particularly owing to the expenses borne for ICT-121 and 140 trial activities. Though these are wrapped up, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shall incur expenses pertaining to ICT-107-Phase II trial follow up and analysis. At the end of March, the company notified of possessing cash worth $25 million, at their disposal.

CEO Ecstatic, Investors Confused?

Andrew Gengos, the CEO of ImmunoCellular stated in the Q1-2014, the company has worked on advancing the development pipeline, making the phase III ready, and worked hard on leveraging the ICT-107 program (that deals with glioblastoma). Further, the CEO sounded ecstatic since the documented ICT-107 Phase II results has already been accepted for an oral session at the ASCO meeting (the most revered consortium of emeritus oncology experts worldwide).

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has carried out extensive research in putting out matured data providing insight into apt survival differences amongst varied trial sub groups. This is expected to help IMUC to identify likely target populace for the Phase III clinical trials. ImmunoCellular has plans to discuss with the regulatory agencies across the U.K and the U.S, seeking a clarified path for the inception of ICT-107 in major markets. IMUC is also progressing squarely on its ICT-140 and ICT-121 programs simultaneously.

Speculations Amidst Expections

Speculations are rife as to whether the imminent presentation at ASCO meet can reignite the IMUC stocks, and whether the emeritus oncologists consider ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)’s data centric researches impactful! The role of the regulatory agencies in letting sales of ICT-107 across target markets is also a cause of concern. The future of the stocks’ trend can further be analyzed post-ASCO meet!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.